338 related articles for article (PubMed ID: 19213230)
1. Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agents.
Sobell JM; Kalb RE; Weinberg JM
J Drugs Dermatol; 2009 Feb; 8(2):147-54. PubMed ID: 19213230
[TBL] [Abstract][Full Text] [Related]
2. From conventional to cutting edge: the new era of biologics in treatment of psoriasis.
Tzu J; Kerdel F
Dermatol Ther; 2008; 21(2):131-41. PubMed ID: 18394087
[TBL] [Abstract][Full Text] [Related]
3. The status of biologic therapies in the treatment of moderate to severe psoriasis.
Menter A
Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
5. [The biological treatments for moderate to severe plaque psoriasis].
Thielen AM; Marazza G
Rev Med Suisse; 2008 Apr; 4(155):1089-90, 1092-4. PubMed ID: 18610721
[TBL] [Abstract][Full Text] [Related]
6. Etanercept provides a more physiological approach in the treatment of psoriasis.
Altomare G; Ayala F; Berardesca E; Chimenti S; Giannetti A; Girolomoni G; Lotti T; Martini P; Peserico A; Guerra AP; Vena GA
Dermatol Ther; 2008 Oct; 21 Suppl 2():S1-14. PubMed ID: 18837727
[TBL] [Abstract][Full Text] [Related]
7. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Alwawi EA; Krulig E; Gordon KB
Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
[TBL] [Abstract][Full Text] [Related]
9. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
Weinberg JM; Saini R
Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
[TBL] [Abstract][Full Text] [Related]
10. [Psoriasis in the era of biologics].
Torres T; Velho GC; Sanches M; Selores M
Acta Med Port; 2010; 23(3):493-8. PubMed ID: 20654269
[TBL] [Abstract][Full Text] [Related]
11. Biologic therapies for psoriasis.
de Felice C; Ardigo M; Berardesca E
J Rheumatol Suppl; 2009 Aug; 83():62-4. PubMed ID: 19661545
[TBL] [Abstract][Full Text] [Related]
12. Long-term data in the treatment of psoriasis.
Thaçi D
Br J Dermatol; 2008 Aug; 159 Suppl 2():18-24. PubMed ID: 18700911
[TBL] [Abstract][Full Text] [Related]
13. Biologic agents in psoriasis.
Lee MR; Cooper AJ
Australas J Dermatol; 2006 Nov; 47(4):217-29; quiz 229-30. PubMed ID: 17034462
[TBL] [Abstract][Full Text] [Related]
14. [Use of biologicals in psoriasis].
Friedrich M; Philipp S; Sabat R; Asadullah K; Sterry W
Z Rheumatol; 2003 Oct; 62(5):439-49. PubMed ID: 14579031
[TBL] [Abstract][Full Text] [Related]
15. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
Fiorino G; Allez M; Malesci A; Danese S
Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
[TBL] [Abstract][Full Text] [Related]
16. Hepatosplenic T-cell lymphomas and therapy with TNF-alpha-blocking biologics: a risk for psoriasis patients?
Beyer M; Steinhoff M; Anagnostopoulos I; Assaf C; Sterry W
J Dtsch Dermatol Ges; 2009 Mar; 7(3):191-4. PubMed ID: 19192165
[TBL] [Abstract][Full Text] [Related]
17. Pediatric psoriasis: updates in biologic therapies.
Sukhatme SV; Gottlieb AB
Dermatol Ther; 2009; 22(1):34-9. PubMed ID: 19222515
[TBL] [Abstract][Full Text] [Related]
18. Off-label use of biologicals in the management of inflammatory oral mucosal disease.
O'Neill ID
J Oral Pathol Med; 2008 Nov; 37(10):575-81. PubMed ID: 18764859
[TBL] [Abstract][Full Text] [Related]
19. [Sequential histological and immunohistochemical assessment of proliferation and apoptotic markers during treatment of psoriasis with antitumor necrosis factor alpha (infliximab)].
Gómez-Mateo C; Avalos-Peralta SP; Ríos-Martín JJ; Carrizosa-Esquivel AM; González-Cámpora R; Camacho-Martínez F
Actas Dermosifiliogr; 2009 Jun; 100(5):420-4. PubMed ID: 19558920
[TBL] [Abstract][Full Text] [Related]
20. The role of lesional T cells in recalcitrant psoriasis during infliximab therapy.
Bovenschen HJ; Van De Kerkhof PC; Gerritsen WJ; Seyger MM
Eur J Dermatol; 2005; 15(6):454-8. PubMed ID: 16280298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
